A Study to Evaluate KarXT Injection
Phase 1
48
about 2.1 years
18–55
8 sites in CA, FL, GA +3
About this study
Researchers are testing different doses of KarXT, a medication, to see how safe it is and what levels are reached in the body. The trial will last for about 772 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take KarXT
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of participants with adverse events (AEs), Number of participants with adverse events of special interest (AESIs), Number of participants with serious adverse events (SAEs)
Secondary: Apparent terminal phase half-life (T-HALF), Apparent total body clearance (CLT/F), Area under the plasma concentration-time curve from time zero to 672 hours (AUC(0-672)), Area under the plasma concentration-time curve from time zero to infinity (AUC(INF)), Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)), Maximum concentration (Cmax), Number of participants with AEs, Number of participants with SAEs
Psychiatry / Mental Health